- Report
- November 2025
- 190 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- June 2025
- 185 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- May 2025
- 183 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- April 2025
- 183 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- December 2025
- 250 Pages
Global
From €3917EUR$4,490USD£3,411GBP
- Report
- July 2025
- 175 Pages
Global
From €3917EUR$4,490USD£3,411GBP
- Report
- January 2026
- 186 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- September 2025
- 185 Pages
Global
From €3925EUR$4,500USD£3,419GBP
- Report
- February 2026
- 193 Pages
Global
From €5103EUR$5,850USD£4,444GBP
- Report
- January 2026
- 120 Pages
Global
From €4143EUR$4,750USD£3,609GBP
- Report
- June 2025
- 400 Pages
Global
From €4317EUR$4,949USD£3,760GBP
- Report
- June 2025
- 400 Pages
Global
From €4317EUR$4,949USD£3,760GBP
- Report
- June 2025
- 150 Pages
Global
From €2354EUR$2,699USD£2,050GBP
- Report
- June 2025
- 150 Pages
Global
From €2354EUR$2,699USD£2,050GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2433EUR$2,789USD£2,119GBP
- Report
- June 2025
- 150 Pages
Global
From €2354EUR$2,699USD£2,050GBP
- Report
- June 2025
- 150 Pages
Global
From €2354EUR$2,699USD£2,050GBP
- Report
- June 2025
- 400 Pages
Global
From €4317EUR$4,949USD£3,760GBP
- Report
- June 2025
- 400 Pages
Global
From €4317EUR$4,949USD£3,760GBP
- Report
- June 2025
- 400 Pages
Global
From €4317EUR$4,949USD£3,760GBP

The Anti Tumour Necrosis Factor (anti-TNF) market is a subset of the Immune Disorders Drugs market. Anti-TNF drugs are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. These drugs work by blocking the action of TNF, a protein that is involved in inflammation and tissue destruction. Anti-TNF drugs are generally administered as injections or infusions, and are often used in combination with other medications.
The anti-TNF market is highly competitive, with a number of companies offering products. These include AbbVie, Amgen, Janssen, Merck, Pfizer, and UCB. Each company has its own portfolio of anti-TNF drugs, and they are continually developing new products to meet the needs of patients. Show Less Read more